We’re excited to see data from our Phase 3 BROADWAY study shared in a late-breaking oral presentation at #NLASessions. Discover what we’ve learned in this study of 2,500 patients at high risk for cardiovascular disease. bit.ly/3T4NL64

Residual risk—which includes lipid levels like Lp(a)—describes everything that still has the potential to increase cardiovascular risk once LDL-C has been addressed. Learn about these additional risk factors associated with cardiovascular disease. bit.ly/3YhIc7J

We’re proud to celebrate Chris Deluzio, our EVP of Sales and Enterprise Operations, as a 2025 Veeva Hero. From pioneering new tools like Vault CRM and Campaign Manager to helping to shape the future on Veeva’s Advisory Board, Chris leads with heart, vision, and purpose.

Hear from our leadership team as part of these upcoming investor conferences in June. Live webcasts and archived replays from each event will be available on our website. bit.ly/4mzNMwu

A seasoned financial leader with over 30 years of experience, Louise Kooij has been instrumental in driving our financial strategy and operations—first as CFO beginning in 2020 and now as Chief Accounting Officer. With a track record of supporting major launches in pharma,

While statins remain the gold standard for lipid lowering, their impact on diabetes progression raises important questions. In a retrospective cohort study of 83,022 matched pairs of patients with diabetes, statin use was associated with a 37% increased relative risk of diabetes

We’re pleased to share positive topline results from our Alzheimer's Disease biomarker analyses in the Phase 3 BROADWAY trial. Full results will be presented on July 30th at #AAIC2025. Learn more about the study: bit.ly/3SIOz0t

We invite you to join our R&D Day webcast on June 11 beginning at 9am ET. Hear from our leadership team as they discuss the latest developments in our clinical program and the future of innovation in cardiovascular care. bit.ly/43UH5gb

🧪 Science-backed. Patient-focused. 🫀 NewAmsterdam Pharma Corporation is advancing lipid-lowering treatments for cardiovascular disease—so patients can live longer, fuller lives. 🎊 Keep pushing boundaries, $NAMS!

We’re excited to join Nasdaq Exchange to wrap up our R&D Day and the trading day by ringing the closing bell. #NasdaqListed

Statins serve as a solid start to lipid-lowering therapy, but many patients need more. Doubling the dose only additionally lowers LDL-C by about 6%, and that pattern holds even at 4x and 8x the dose. For many patients struggling with persistently high LDL-C, higher dose statins

Lowering LDL-C isn’t just about numbers—it’s about outcomes. Every 39 mg/dL reduction in LDL-C is linked to an ≈23% decrease in major adverse cardiovascular events (MACE). Even small changes can make a big impact. Learn more about the benefits of LDL-C reduction:

Despite current standards of care, many patients are still not meeting their LDL-C goals, leaving them at risk for cardiovascular events like heart attack and stroke. The American College of Cardiology and American Heart Association have released updated guidelines for managing acute coronary syndromes,

Maryellen McQuade, our Chief People Officer, brings deep expertise in organizational development and change management gathered over 25+ years in HR leadership roles across leading pharmaceutical and biotech companies. She has guided HR strategy through significant

Reducing high LDL-C is an essential part of mitigating cardiovascular risk, but as our Chief Scientific Officer Dr. John Kastelein explains, it’s not the only factor. Learn more about residual risk: bit.ly/467tW69

The curtain is about to rise at #AAIC2025, where full results from the Alzheimer’s biomarker prespecified analysis from our BROADWAY LDL-C lowering study will be shared in a Developing Topics oral presentation. Make plans to join us at AAIC: bit.ly/4lOSxBO

BREAKING: Our investigational CETP inhibitor significantly delayed progression of p-Tau217, an Alzheimer’s disease biomarker, in a 12-month prespecified analysis of data from our BROADWAY ASCVD trial. Effects were most pronounced in ApoE4 carriers. Explore our findings:

p-Tau217 is emerging as an important biomarker that can be used to help diagnose and monitor Alzheimer’s disease progression. Levels increase years before memory symptoms appear, making it a helpful indicator for early detection. Get to know this powerful biomarker:

We’ve had a strong start to 2025, sharing compelling new data at multiple conferences and continuing to support our Phase 3 PREVAIL cardiovascular outcomes trial. Review our corporate update and second-quarter financial results: bit.ly/3J8iVYF

A growing body of research indicates CETP plays a central role in both systemic and brain lipid metabolism. Genetic studies show those with naturally low CETP levels are at a lower risk of Alzheimer’s disease, particularly in ApoE4 carriers. Learn more about this emerging link: